Akari Therapeutics (AKTX) Change in Accured Expenses (2014 - 2026)
Akari Therapeutics' (AKTX) quarterly Change in Accured Expenses came in at $931000.0 in Q1 2026, up 92.75% year-on-year from $483000.0 in Q1 2025, and up 611.54% quarter-over-quarter from -$182000.0 in Q4 2025.
Akari Therapeutics (AKTX) Change in Accured Expenses (2014 - 2026) Analysis & Trends
Akari Therapeutics has disclosed Change in Accured Expenses across 9 years of filings, most recently posting $931000.0 for Q1 2026.
- Change in Accured Expenses for Q1 2026 came in at $931000.0, up 92.75% year-over-year; the trailing twelve-month figure through Mar 2026 was -$550000.0 (down 112.95% YoY), and the FY2025 annual result was -$998000.0, down 119.11% from the prior year.
- Change in Accured Expenses came in at $931000.0 for Q1 2026 at Akari Therapeutics, up from -$182000.0 in the prior quarter.
- In the past five years, Change in Accured Expenses ranged from a high of $1.5 million in Q2 2024 to a low of -$704000.0 in Q3 2025.
- The 4-year median for Change in Accured Expenses is -$100000.0 (2023), against an average of $324615.4.
- Across the five-year window, Change in Accured Expenses soared 1441.0% in 2024 and sank 175.37% in 2025, its largest moves.
- Akari Therapeutics' Change in Accured Expenses stood at -$100000.0 in 2023, then jumped by 1441.0% to $1.3 million in 2024, then slumped by 113.57% to -$182000.0 in 2025, then jumped by 611.54% to $931000.0 in 2026.
- The last three Change in Accured Expenses figures came in at $931000.0 (Q1 2026), -$182000.0 (Q4 2025), and -$704000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - | - |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - | - |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - | 931,000.00 |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - | - |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - | 644,700.00 |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn | 70.50 Mn |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - | - |
| 10 | Regeneron Pharmaceuticals | 63.59 Bn | 54.83 Bn | 3.31 Bn | 107.70 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 931,000.00 |
| Mar 31, 2026 | 931,000.00 |
| Dec 31, 2025 | -182,000.00 |
| Dec 31, 2025 | -182,000.00 |
| Sep 30, 2025 | -704,000.00 |
| Sep 30, 2025 | -704,000.00 |
| Jun 30, 2025 | -595,000.00 |
| Jun 30, 2025 | -595,000.00 |
| Mar 31, 2025 | 483,000.00 |
| Mar 31, 2025 | 483,000.00 |
| Dec 31, 2024 | 1.34 Mn |
| Dec 31, 2024 | 1.34 Mn |
| Sep 30, 2024 | 934,000.00 |
| Sep 30, 2024 | 934,000.00 |
| Jun 30, 2024 | 1.49 Mn |
| Jun 30, 2024 | 1.49 Mn |
| Mar 31, 2024 | 1.46 Mn |
| Mar 31, 2024 | 1.46 Mn |
| Dec 31, 2023 | -100,000.00 |
| Dec 31, 2023 | -100,000.00 |